Scientific Sessions 2025  /  Biological and Pragmatic Interventions in Heart Failure: From Present to Future  /  Discussant: DAPA-EAT
Logo

American Heart Association

  40
  0

Final ID:

Discussant: DAPA-EAT

  • Fontana, Marianna  ( University College London , London , United Kingdom )
  • Raman, Subha  ( OhioHealth , Columbus , Ohio , United States )
    • Author Disclosures:
    Marianna Fontana: DO have relevant financial relationships ; Consultant:Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium:Active (exists now) ; Individual Stocks/Stock Options:Mycardium (shares):Active (exists now) ; Individual Stocks/Stock Options:LexeoTherapeutics (share options):Active (exists now) ; Other (please indicate in the box next to the company name):Alnylam, Bridgbio, Astrazeneca, Pfizer.(research grants):Active (exists now) | Subha Raman: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Biological and Pragmatic Interventions in Heart Failure: From Present to Future

Sunday, 11/09/2025 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Discussant: The MAPLE-HCM Trial

Day Sharlene

Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure - BioVAT-HF-DZHK20 – Phase II Interim Data Report

Ensminger Stephan, Fujita Buntaro, Gerecke Birgit, Hasenfuss Gerd, Hellenkamp Kristian, Herrmann-lingen Christoph, Jebran Ahmad-fawad, Jurczyk Dominik, Kowallick Johannes, Legler Tobias, Lotz Joachim, Kutschka Ingo, Placzek Marius, Puehler Thomas, Riggert Joachim, Sadlonova Monika, Tiburcy Malte, Zimmermann Wolfram, Paitazoglou Christina, Seidler Tim, Brandenburg Soeren, Anker Stefan, Bremmer Felix, Eitel Ingo, Friede Tim

More abstracts from these authors:
Meet the Trialist: Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study

Fontana Marianna

Stiffen Up: Evaluation of HFpEF in the Patient with Cancer

Fontana Marianna, Sarswat Nitasha, Ruberg Frederick

You have to be authorized to contact abstract author. Please, Login
Not Available